The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution Update

27 Jun 2005 06:00

Embargoed: 27 June 2004 Akers Biosciences, Inc. ("Akers" or the "Company") Re. UK Distribution Agreement Akers Biosciences, Inc. is pleased to announce the launch of a number of itsproducts in the UK through its UK distribution agent Advanced Rapid DiagnosticsLimited ("ARD"). ARD was established in order to penetrate the UK markets withAkers' growing range of products.The Company is already actively marketing a number of CE approved products inthe UK through ARD which, among others, include:Tests for `drugs of abuse'Akers has developed a suite of tests for `drugs of abuse' including tests foruse of methadone, heroine, cocaine, marijuana and ecstasy among others. Forthis product ARD is targeting the public service markets alongside retailbusinesses or, indeed, any organisation wishing to have the ability to performrapid tests on staff. The Company believes that there is significant potentialfor law enforcement agencies or educational establishments to adopt thesetests.Alcohol BreathalyzersARD is marketing Akers' range of alcohol breathalyzers in the UK to a range ofindustries, in particular transport businesses operating any form of vehicles,be they rail, air, road or sea. In addition to ensuring transportation safety,the use of these products may also positively impact insurance costs for thesebusinesses. ARD will also be looking to penetrate retail markets including highstreet pharmacies so that the public will have access to affordable tests toshow alcohol levels, with particular emphasis on self-regulation in the case ofdriving.PIFA‚® Heparin/PF4 test for heparin-induced thrombocytopenia and thrombosissyndrome (HITTS)Following increasing levels of penetration in the United States and Canada forthis test, the first rapid test for heparin/platelet factor-4 antibodies, ARDwill be initially targeting the private healthcare sector in the UK. Heparin isa widely used intravenous anticoagulant in the United Kingdom. Intravenousheparin is commonly used for the prophylaxis and treatment of thromboembolicdisease, as well as numerous other applications including certain types of lungand heart disorders, and during or after a variety of surgeries including openheart, bypass, dialysis and orthopedic procedures. Heparin is also used fordiagnostic and therapeutic interventional radiologic procedures. Akers' test isable to identify, almost instantly, patients at risk for developing HITTS as aresult of administering of heparin. This is particularly crucial in cases ofemergency surgery. Patients identified by the test as being at risk can beprescribed alternative drugs in order to avoid, potentially, fatal reactions toheparin.Cholesterol TestsBlood cholesterol consists of HDL cholesterol (often called "good cholesterol")and LDL cholesterol (often called "bad cholesterol"). The risk of heart diseaseis related to HDL levels, total cholesterol levels, and other risk factors. TheAkers Biosciences Tri-Cholesterol Test Kit is the only FDA-approved rapid assaythat provides a complete cholesterol profile of the patient, withsemi-quantitative determinations of high-density lipoprotein (HDL) cholesterol,low-density lipoprotein (LDL) cholesterol, and total cholesterol levels inwhole blood obtained from a finger stick. The test is designed for routinemonitoring of cholesterol levels right in a physician's office or directly athome.Dr. Raymond Akers, Chief Executive, Akers Biosciences, Inc. commented,"We are now enjoying very encouraging levels of sales for many of our productsin the United States and other parts of the world and I am delighted to beembarking upon an aggressive marketing and sales drive in the UK. As is thecase in the US, many of our products will be completely unique in the UK,enabling crucial tests to be performed rapidly and accurately. There is agrowing need for tests for alcohol levels and use of drugs of abuse all overthe world. Our tests in this area will enable people, particularly in thetransport and education industries to identify situations of abuse instantly.As for our PIFA Heparin PF-4 test, we believe this test will help save lives inthe UK. In addition, the medical industry can save millions of pounds inheparin-related law suits of patients who have suffered symptoms of a drugwhose prescription could have been avoided through identification of risk withour test and the prescription of an alternative."Dr. Raymond AkersChief Executive, Akers Biosciences, Inc.Tel. 020 7917 9476Barry ParkerChief Executive, Advanced Rapid Diagnostics LimitedTel. 0161 792 1112Ben SimonsHansard CommunicationsTel. 020 7245 1100ENDAKERS BIOSCIENCES INC
Date   Source Headline
25th Jul 20074:42 pmRNSDirector/PDMR Shareholding
25th Jul 20072:54 pmRNSDirector/PDMR Shareholding
18th Jul 20077:01 amRNSDirector/PDMR Shareholding
18th Jul 20077:00 amPRNDirector Shareholding - Restatement
17th Jul 20077:00 amPRNAppointment of CFO
6th Jul 200712:35 pmPRNIssue of Equity
3rd Jul 20077:00 amPRNDirector/PDMR Shareholding
29th Jun 20071:27 pmRNSAnnual Report and Accounts
29th Jun 20078:26 amRNSDirector/PDMR Shareholding
26th Jun 20077:00 amPRNFinal Results
3rd May 20077:00 amPRNUnited States Military Contract
26th Mar 20077:00 amPRNUK Distribution Agreement
22nd Mar 20077:00 amPRNUK Orders
15th Mar 20077:00 amPRNDirectorate Change
14th Mar 20073:52 pmRNSAdditional Listing
9th Mar 20073:14 pmRNSAdditional Listing
20th Feb 20077:00 amPRNStrategic Update
6th Feb 20079:17 amRNSAdditional Listing
1st Feb 20077:00 amPRNDirector Share Purchase
24th Jan 20077:00 amPRNAcquisition
18th Jan 20077:00 amPRNTrading & Product Update
3rd Jan 20074:40 pmRNSDirector/PDMR Shareholding
21st Dec 200611:52 amRNSTotal Voting Rights
14th Dec 20067:00 amPRNExpansion of Home Diagnostic Product Line
10th Nov 20062:27 pmRNSIssue of Equity
30th Oct 20067:00 amPRNDistribution Agreement
24th Oct 20069:36 amRNSIssue of Equity
20th Oct 20063:32 pmRNSAdditional Listing
11th Oct 20067:00 amPRNU.S. Department of Transport Approval
4th Sep 200611:18 amRNSAdditional Listing
23rd Aug 20064:43 pmRNSAdditional Listing
4th Aug 20064:24 pmRNSAdditional Listing
30th Jun 20064:50 pmRNSAnnual Report and Accounts
11th May 20067:00 amPRNDirectorate Change
10th May 20067:00 amPRNResult of AGM
3rd May 20067:00 amPRNFDA Clearance for Rapid Alcohol Breathalyzers
24th Apr 20064:00 pmRNSHolding(s) in Company
4th Apr 20067:00 amPRNFinal Results
3rd Apr 20061:09 pmPRNMajor Distribution Agreement
3rd Mar 20064:03 pmRNSAdditional Listing
28th Feb 20067:00 amPRNAcquisition of WNCK, Inc.
13th Feb 20067:00 amPRNTrading Update
3rd Feb 200612:52 pmRNSAdditional Listing
30th Jan 200610:41 amRNSHolding(s) in Company
27th Jan 20061:34 pmRNSIssue of Equity
3rd Jan 20067:00 amPRNRe. Increased Production Facilities
28th Dec 20053:30 pmRNSHolding(s) in Company
19th Dec 20059:53 amRNSIssue of Equity
9th Dec 20055:46 pmRNSDirector/PDMR Shareholding
30th Nov 200511:27 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.